Gyre Therapeutics (NASDAQ:GYRE) Trading Up 8.2% – Should You Buy?

Gyre Therapeutics, Inc. (NASDAQ:GYRE) was up 8.2% during mid-day trading on Monday . The stock traded as high as $8.86 and last traded at $8.9150. Approximately 77,539 shares traded hands during trading, an increase of 5% from the average daily volume of 73,646 shares. The stock had previously closed at $8.24.

Analysts Set New Price Targets

GYRE has been the topic of several research reports. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Gyre Therapeutics in a research report on Thursday, January 22nd. Wall Street Zen upgraded Gyre Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, November 15th. Finally, Zacks Research upgraded Gyre Therapeutics from a “strong sell” rating to a “hold” rating in a report on Friday, November 14th. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Gyre Therapeutics currently has an average rating of “Hold” and an average target price of $17.00.

Gyre Therapeutics Trading Up 6.1%

The company has a market cap of $841.95 million, a PE ratio of 291.43 and a beta of 1.97. The firm has a 50 day moving average of $7.78 and a two-hundred day moving average of $7.77.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. State of Alaska Department of Revenue bought a new stake in shares of Gyre Therapeutics during the third quarter valued at approximately $38,000. Bank of America Corp DE boosted its stake in Gyre Therapeutics by 28.8% during the 2nd quarter. Bank of America Corp DE now owns 6,277 shares of the company’s stock valued at $46,000 after purchasing an additional 1,402 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in shares of Gyre Therapeutics by 84.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 6,461 shares of the company’s stock worth $47,000 after purchasing an additional 2,961 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Gyre Therapeutics by 77.8% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,413 shares of the company’s stock valued at $54,000 after purchasing an additional 3,244 shares in the last quarter. Finally, Dimensional Fund Advisors LP bought a new position in Gyre Therapeutics during the 4th quarter valued at about $77,000. 23.99% of the stock is owned by hedge funds and other institutional investors.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company’s proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.

Gyre’s preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer’s disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.